ANI Pharmaceuticals, Inc.
ANIPANI Pharmaceuticals, Inc. (ANIP) is a pharmaceutical company that develops, manufactures, and markets a broad portfolio of generic and branded prescription drugs. Founded in 2007 and headquartered in Schaumburg, Illinois, the company focuses on producing high-quality, affordable medications across various therapeutic areas, including CNS, cardiovascular, and women's health. ANI emphasizes leveraging its formulation expertise and a robust pipeline to meet the needs of healthcare providers and patients.
Company News
Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather t...
CG Oncology announced that its leadership will participate in two upcoming investor conferences in September 2025, presenting at the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference.
Cg Oncology reported a wider net loss in Q2 2025, with no revenue and increased R&D expenses. The company continues developing a gene therapy for bladder cancer and plans to submit a Biologics License Application in Q4 2025.
ANI Pharmaceuticals reported record quarterly net revenues of $197.1 million, a 43.4% year-over-year growth. The company's Rare Disease business generated $69.0 million in quarterly net revenues and presented preclinical data on the use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis mouse model.
ANI Pharmaceuticals reported strong Q4 results, with adjusted EPS and sales beating estimates. The company raised its 2025 guidance for revenue and adjusted EPS, driven by growth in its Cortrophin Gel, generics, and branded products.
